Pharmaceutical Technology

JULY 8, 2022

Xenetic Biosciences and Catalent Pharma Solutions have signed an agreement for the cGMP manufacturing of the Xenetic’s recombinant protein, Human DNase I. The DNase platform can potentially act on neutrophil extracellular traps (NETs), which are web-like structures made of extracellular chromatin covered with histones and other proteins.

Manufacturing 147

Manufacturing Protein Clinical Development Development 147

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Roots Analysis

MAY 21, 2024

Proteins are the chains of amino acids linked together in different combinations and perform a wide variety of functions. However, continuous regulation of the cellular proteome is essential for maintaining the right balance of different proteins necessary for normal cellular function, survival, and proliferation.

Protein 40

Protein Marketing Development Antibody 40

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

MAY 9, 2023

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130

Drugs Clinical Development Antibody Protein 130

pharmaphorum

DECEMBER 4, 2020

Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development. VLA15 is the only active Lyme disease vaccine in clinical development today, and covers six strains that are prevalent in North America and Europe.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

pharmaphorum

APRIL 28, 2022

The platform combines biochemistry, native mass spectrometry, and custom chemistry to investigate protein interactions within a cellular ecosystem, whilst filtering out the “confounding complexity” of other factors in the cell, according to the biotech. Robinson is OMass’ founder and scientific advisor.

Protein 105

Protein Drugs Development Clinical Trials 105

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

BioTech 365

OCTOBER 14, 2020

DUBLIN–(BUSINESS WIRE)–The “Protein Kinase Inhibitors in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

Protein 40

Protein Business Development Clinical Development Development 40

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. It targets 4-1BB (CD137) protein mainly expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. It targets 4-1BB (CD137) protein mainly expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. A recombinant protein-based Covid-19 vaccine, IndoVac received EUA in the country as a primary shot in adult patients.

Vaccination 130

Vaccination Vaccine Development Production 130

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. The company works in partnership with other pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

DECEMBER 6, 2022

Under a possible development and commercialisation agreement in the future for the CMV vaccine candidate discovered by the parties, Evaxion will be entitled to receive upfront and milestone payments from ExpreS 2 ion.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Protein 40

Protein Development Genome Genomics 40

BioPharma Reporter

JULY 12, 2021

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiTheraâs COVID-19 vaccine candidate, according to Phase 2 preliminary data.

Vaccination 105

Vaccination Vaccine Protein Antibody 105

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. It conducts research and development to develop protein drugs, antibody therapeutics to target claudin essential proteins and siRNA therapeutics, to target E6, E7 oncogenes, and others.

Protein 100

Protein Drugs Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JULY 7, 2022

Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

pharmaphorum

APRIL 19, 2022

The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO53, another DMD candidate. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Clinical Development Production 105

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics.

Protein 100

Protein Engineer Drugs Clinical Trials 100

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. (Nasdaq: ARVN) and Pfizer Inc.

Protein 52

Protein Development HR Hormones 52

XTalks

APRIL 2, 2025

Along the way, Dr. Fordyce has built a world class team of drug developers and raised over $1 billion in capital. Dr. Fordyce previously worked in clinical development leadership roles at Gilead Sciences in the 2010s, driving innovation in treatments for HIV and hepatitis.

Life Science 59

Life Science Clinical Development Development Trials 59

pharmaphorum

MAY 13, 2021

These allow the body to produce a correct version of the misfolded dystrophin protein that is the root cause of DMD. But gene therapies go one step further by inserting the dystrophin gene into the patient’s muscle tissue, in order to produce a working version of the protein that is essential for building muscles.

Gene Therapy 102

Gene Therapy Gene Trials Protein 102

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. These are developed based on Atrize platform technology. Aprea Therapeutics overview Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

Production 100

Production Clinical Trials Clinical Trials Development 100

pharmaphorum

SEPTEMBER 14, 2020

It uses a weakened, non-replicating, version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 coronavirus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccination 104

Vaccination Vaccine Trials Protein 104

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

pharmaphorum

JANUARY 25, 2021

With over 23 world-class speakers set to share their ground-breaking research developments, straight to your home or office, this is your chance to learn from the industry’s very best, including: Mitokinin showcasing how activating PINK1 dependent mitochondrial quality control to treat Parkinson’s disease. Don’t miss out!

Development 98

Development Drugs Protein Clinical Development 98

XTalks

DECEMBER 5, 2023

As its active ingredient, repotrectinib inhibits the proto-oncogene tyrosine-protein kinase ROS1 and the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB and TRKC. The encouraging results also suggest that further clinical development of unecritinib is justified, particularly for NSCLC cases involving ALK rearrangements.

Protein 115

Protein FDA Approval Medicine Trials 115

pharmaphorum

DECEMBER 21, 2021

The Kadmon deal also included an immuno-oncology candidate – anti-PD-L1/IL-15 fusion protein KD033 – which is in early clinical development. Sanofi’s other acquisitions this year were the $3.2 billion takeover of mRNA specialist Translate Bio , firming up a longstanding alliance with the biotech, and a $1.9

Licensing 124

Licensing Licensing Protein Clinical Development 124

Pharmaceutical Technology

JUNE 2, 2023

The company acquired the global rights to develop and commercialise clinical-stage Toll-like receptor 7 and 8 (TLR7/8) agonist immunomodulators from the Edison, New Jersey-based Seven and Eight Biotherapeutics. The company’s platform measures the real-time movement of individual proteins and protein populations in living cells.

Protein 130

Protein Development Clinical Development DNA 130

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein. It was also under development for the treatment of Huntington’s disease and traumatic brain injury.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein. It was also under development for the treatment of Huntington’s disease and traumatic brain injury.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100